Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer
about
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugsDifferences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese populationPersonalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinibDistinctive Patterns of Initially Presenting Metastases and Clinical Outcomes According to the Histological Subtypes in Stage IV Non-Small Cell Lung CancerIntergenically Spliced Chimeric RNAs in Cancer.TINAGL1 and B3GALNT1 are potential therapy target genes to suppress metastasis in non-small cell lung cancer.Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity.Mutant KRAS promotes malignant pleural effusion formation.Clinical Significance and Next-Generation Sequencing of Chinese Pulmonary Sarcomatoid Carcinoma.Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.Mortality outcomes of low-dose computed tomography screening for lung cancer in urban China: a decision analysis and implications for practiceEGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysismiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type.Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysisNon-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset.Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patientsGli1 mediates lung cancer cell proliferation and Sonic Hedgehog-dependent mesenchymal cell activation.Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in TaiwanClinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysisOverview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement.ALK-rearranged squamous cell lung cancer: a case report.MiR-133a is downregulated in non-small cell lung cancer: a study of clinical significance.Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver MutationsClinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer.Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma.Adenocarcinoma of the lung with concomitant ALK fusion gene and EGFR gene mutation: A case report and literature reviewTargeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy.Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health InitiativeLung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature.Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patientsClinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China.Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features.Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas.
P2860
Q26769659-399B8DA4-FFA4-4632-8A74-6A399E42E7AAQ26786594-584A44C2-BA4D-4D32-9FF6-0023EC818FBBQ28083711-3B6A96DF-AAA3-4D5B-BD5B-393A4E22168AQ28387027-805B1AA4-A301-4265-98DA-9827035E4944Q30274742-C7CBC7C3-FB5B-487E-B458-5C7F177E6FC5Q30369946-1AE896BC-BA18-42CC-8F14-C3894332E806Q31167585-ABF72462-4F80-482D-8361-F53EB4FE99FBQ33617464-554C1CA3-72DA-4E25-9691-C877DCCC3AF1Q33716297-B731FACC-B1FB-4356-9EDB-66D61A57A29DQ33822393-400D6FCA-C254-416D-8539-3165078191EFQ33844713-F12CE405-BA92-4A98-9EEE-E3EF674001FCQ33908633-06E3D7E9-16EA-4143-BED1-F7535CC2BF21Q34167004-E34A3A0B-2452-45D5-A44C-4E736983ACC3Q34365935-E1B777D4-34C8-4028-BF7E-D0BE4750A047Q34434003-83FE66F4-65B9-42A0-939B-1A04F9C8B95DQ34558586-EB7EF231-5727-4A44-9037-E3627843BE69Q34688871-3F8EDECE-01D5-4812-8658-382EDAF6A820Q34718073-9754952E-3568-4A24-8E88-C956D66169E6Q34947842-1546B331-6D16-4B39-938C-F8891B9632D5Q35113209-78F9AD50-AB7C-405E-851F-DBF11761DA46Q35256603-AEEF9B01-F408-45AE-B3FD-FF85E7369ED4Q35404897-3D1D139A-82E2-4C99-B502-AC73F7AA7FFCQ35537955-B996A063-37DC-4701-937D-32AE12F54DFDQ35837368-EB004C52-1BD4-43C4-8E16-072B323EFFABQ35909271-1B72BCD2-B54F-4E8E-B46E-CE6FC83C7F38Q36250691-8B2773E4-B8F6-45DA-A76D-2B677B640983Q36335816-438BDDDA-4C02-4DAF-A9C9-0CC5E1CE4C04Q36477735-879781FB-30DF-431C-999C-DADDDB180CE3Q36523885-EF9C8ACA-70D4-4938-8C30-26D38BD7F28DQ36545592-3BCC5531-A0C6-475A-83F7-281D9944B8B7Q36866859-2E2AA785-5C42-4560-A497-C6A1E24C3653Q36914478-BA690205-A177-41F6-B24A-94006A5EB107Q37114965-C70068AD-904E-4F41-A9D7-FCC68E1D5077Q37152528-96E6AE04-3BC7-40C7-9C03-9EE9568BEFEDQ37269159-1D990534-03C0-4FA8-9964-6F1B712C6CE0Q37416902-DE7889AA-B1D0-4A2C-AB88-1242112B6A00Q37566819-F582EAC5-17CA-4743-9EEF-39994C329DFBQ37580410-02C84677-CDD3-4174-9E0D-80140B1EB367Q38863719-89878933-67B6-40A9-A1A6-E1616DB46E56Q41233667-39DC405C-F3BE-4F66-95D7-1718E2F5112D
P2860
Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Clinical significance of EML4- ...... ith non-small cell lung cancer
@ast
Clinical significance of EML4- ...... ith non-small cell lung cancer
@en
Clinical significance of EML4- ...... ith non-small cell lung cancer
@nl
type
label
Clinical significance of EML4- ...... ith non-small cell lung cancer
@ast
Clinical significance of EML4- ...... ith non-small cell lung cancer
@en
Clinical significance of EML4- ...... ith non-small cell lung cancer
@nl
prefLabel
Clinical significance of EML4- ...... ith non-small cell lung cancer
@ast
Clinical significance of EML4- ...... ith non-small cell lung cancer
@en
Clinical significance of EML4- ...... ith non-small cell lung cancer
@nl
P2093
P2860
P1433
P1476
Clinical significance of EML4- ...... ith non-small cell lung cancer
@en
P2093
Hongyu Liu
Qinghua Zhou
Yongwen Li
P2860
P304
P356
10.1371/JOURNAL.PONE.0052093
P407
P50
P577
2013-01-14T00:00:00Z